BioSpace News Archive

Resverlogix Corp. announced that it has closed a one-year extension of Company’s US$6.0 million 10% secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd., and payment of accrued interest thereon, extending the maturity date to May 13, 2023.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that new data from the Phase 1 OPTIC study of ADVM-022 (AAV.7m8-aflibercept) in wet age-related macular degeneration (wet AMD) will be presented during The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announces U.S. Food and Drug Administration (FDA) has granted approval to the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Mestinon® (Pyridostigmine Bromide Syrup) 60 mg/5mL.

BioSig Technologies, Inc. today announced that the Company would be exhibiting at Heart Rhythm 2022, due to take place on April 29 – May 1, 2022 at the Moscone Center in San Francisco, CA.

Synaptogenix, Inc. (Nasdaq: SNPX) (“the Company”), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health (“NIH”) sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer’s disease (“AD”).

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing.

Horizon Therapeutics plc announced the kickoff of the second annual global innovation challenge, The Horizon Prize powered by MIT Solve.

BioFlyte, a biodetection company with a revolutionary new class of fieldable biological threat collection, detection, and identification solutions, today announced that it raised $6.1M in new financing led by Cottonwood Technology Fund with additional funding from existing investor Anzu Partners.

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that it submitted an Investigational New Drug Application (IND) for an observational study to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

As a member of the initiative, Pangaea will apply its novel unsupervised natural language processing, natural language generation and automatic machine learning frameworks to address important issues in healthcare in a privacy preserving manner.